Role of next generation sequencing in clinical care
|
|
- Vernon Bradley
- 5 years ago
- Views:
Transcription
1 Role of next generation sequencing in clinical care Anne Slavotinek Division of Genetics, Department of Pediatrics, UCSF Structure 1. Next generation technologies 2. Consent and secondary findings 3. Genetics of diabetes/clinical examples 1
2 Sanger sequencing National Human Genome Research Institute's Talking Glossary Sanger sequencing 2
3 Exome sequencing Illumina - exons are variably covered - fill in can improve coverage Exon Coverage Sarah Garcia, Personalis 3
4 Whole exome sequencing (WES) What is an exome? -protein encoding regions of genes -1-2% of genome, but 85% mutations % of exome covered Uses of whole exome sequencing: -non-specific phenotypes e.g. intellectual disability -atypical presentations -rare, novel phenotypes -phenotypes difficult to confirm with clinical testing -diseases where testing is expensive -typically sent as a trio with both biological parents From: Korf and Rehm, New Approaches to Molecular Diagnosis Figure Legend: Date of download: 9/6/2014 Copyright 2014 American Medical Association. All rights reserved. 4
5 What to expect? Type of Mutation Novel Non-Novel Total Missense 303 (AA) /192 (C) 10,828/9,319 11,131/9,511 Nonsense 5/5 98/89 103/93 Synonymous 209/109 12,567/10,536 12,776/10,645 Splice 2/2 36/32 38/34 Total 520/307 23,529/19,976 24,049/20,283 AA = African American C = Caucasian 3 general types of results: - positive - negative - variant of uncertain significance (VUS) Bamshad et al., general categories of results: - primary findings - secondary findings Exome Sequencing Sequence variants need to be sorted to find relevant ones: 1) Deleteriousness of variant -frameshift, nonsense > missense -sequence conservation; protein domain -SIFT, PolyPhen-2, Mutation Taster, CADD 2) Existing biological/functional information -segregation with disease -variant not seen in unaffected individuals -expression pattern -predicted function; pathway/gene interactions -animal models Jessica van Ziffle 5
6 Diagnostic Yield/Discovery De Ligt et al,. NEJM, patients with ID - trio approach -total yield 16% Srivastava, Ann Neurol, patients with neurodevelopmental disabilities -total yield 41% -19 AD, 11 AR, 1 X-linked, 1 AD and AR -changed management in all situations -yield depends on testing indication Whole exome sequencing - exome is being considered earlier - exotyping - phenotyping, genotyping, reinterpretation of phenotypic data (Pinto et al., 2016) - digenic diseases and blended phenotypes Whole genome sequencing - analysis of deep intronic regions, non-coding RNA, regulatory regions Glissen et al., trios with severe ID; array and exome negative - WGS had yield of 42% (13 SNVs and 8 CNVs) - no mutations in regulatory regions 6
7 Panel Sequencing - panel targets <150, not 24,000 genes - all exons are sequenced - insertions/deletions detected; algorithm vs exon array - use a panel when clinical evaluation suggests a diagnosis - will not result in secondary/incidental findings - may still result in variants of unknown significance Exome Sequencing There are THREE outcomes from arrays/panel testing: - we may find the cause of the condition in you and your family - we may NOT find the cause of the condition in you and your family - we may get a result that we cannot interpret There are FIVE outcomes from WES testing: The previous three PLUS -we may find another change in the DNA of medical significance but not for the condition we tested you for -we may find family relationships to not be what you thought they were (misattributed parentage) Bob Nussbaum 7
8 Exome sequencing Advantages of WES: -syndromes with high genetic heterogeneity -syndromes that are incompletely characterized -Neveling et al., WES covers 81% of known pathogenic mutations on gene sets -improved diagnostic yield compensates for reduced sensitivity - even if all genes that could have been ordered by physicians had been tested, the larger number of genes captured by the exome would still have led to a clearly superior diagnostic yield at a fraction of the cost Elements of Consent Bick and Dimmock, basic genetics (genes, mutations) -inheritance patterns -penetrance and expressivity -types of DNA variants (pathogenic, benign, VUS) -incidental findings -false positives, false negatives -scientific discoveries that may result from test results -interaction of genes, environment -information privacy -non-paternity -Genetic Information Nondiscrimination Act of
9 Limits to informed consent - Can you really give informed consent when you look so widely [at the genome]? Is that manageable for patients?... (patient representative) - In any case I think that it's very naïve to think that a patient is more able to choose [which results to receive] when he knows more. There are limits to what patients can comprehend. Decision-making in principle does not get easier, the more elaborately a patient is informed.the quality is important and also a discussion... (ethicist) - greater detail can lead to less understanding - overwhelming; information overload - thousands variants identified; need biological parents for interpretation - only variants relevant to presentation reported - if parental samples included, only one report generated Elements of Consent Limitations -not every gene tested / not 100% coverage -not all kind of DNA variants -not all genetic changes in exome -current genetic knowledge not comprehensive Familial relationships/consanguinity Protection against genetic discrimination Secondary findings -different depending on labs -possible information on parents 9
10 Secondary Findings Green et al., Genet Med, 2013 Results not related to the indication for ordering the test, but that may, nonetheless, be of medical value or utility to the ordering physician or patient ACMG recommendations: -actively look for known pathogenic or expected pathogenic variants -59 genes, 24 conditions -prevention and/or treatment available -may be asymptomatic for a long time -excludes conditions screened by NBS -in proband AND for family members (if WES performed), irrespective of proband results -..failure to report a laboratory test result conveying the near certainty of an adverse yet potentially preventable medical outcome would be unethical. Interpretation of Secondary Findings Goal: Maximize positive predictive value LOW SENSITIVITY High false negative rate Data as generated by WES, not same standard as primary variant finding -recommendations to be reviewed periodically -system to submit new genes Amendola et al., 2015 European ancestry 112 genes medically actionable genes: 2.0% ACMG 56: 0.7% African ancestry 112 genes medically actionable genes: 1.1% ACMG 56: 0.5% 10
11 Secondary Findings - Considerations Burke et al., 2013: -screening results, not diagnostic test results -ascertainment bias, as mutations identified in those with disease -unknown natural history -phenotypic spectrum and penetrance not known -lack of controlled studies regarding interventions -prior probability of disease is low -costs should not be generated if patients do not wish for results Shahmirzadi et al., /200 (93.5%) chose to receive 1 categories of IF -manageable if consented well, understand implications -conditions/sequence variants need to be curated Importance of reinterpretation of negative results 11
12 Genetics of Familial Hyperinsulinism (FHI) - hypoglycemia (neonatal onset, mild to severe) (Glaser, 2013) Autosomal recessive ABCC8 (45%) /KCNJ11 (FHI-K ATP ) (5%) - associated with large for gestational age infants - severe refractory hypoglycemia with poor response to medical management - may require pancreatic resection Autosomal dominant ABCC8/KCNJ11 (FHI-K ATP ) - normal for gestational age - present around one year of age (2 d - 30 y) - responds to diet, diazoxide - other genes include GLUD1 (5%), HNF4A (5%), GCK, HADH, UCP2 (<1%) Genetics of Familial Hyperinsulinism (FHI) FHI - good situation for gene panel testing -diagnosis relatively straightforward -genetically heterogeneous -known genes explain much of genetic variation -panels vary in number of genes included and gene coverage -want to do both sequencing analysis and del/dup testing -Panel 1: ABCC8, AKT2, AKT3, GCK, GLUD1, HADH, HK1, HNF1A, HNF4A, INS, INSR, KCNJ11, PDX1, PGM1, SLC16A1, UCP2 -coverage: 96% at 20x -Panel 2: 50 genes; includes some metabolic conditions -panel includes non-coding variants; omits some exons 12
13 Genetics of MODY Anik et al., % of DM in Europe; 21 45/1,000,000 children and 100/1,000,000 adults -monogenic (AD) inheritance -early onset of DM (<25 y) -lack of autoimmune process/insulin resistance with lack of obesity -endogenous insulin secretion is preserved -80% are misdiagnosed as T1D, T2D ->10 known genes -GCK, HNF1A, HNF4A, and HNF1B genes commonest causes in UK -represent 32%, 52%, 10%, and 6% of MODY respectively -another good situation for gene panel testing Examples of available panels: Genetics of MODY Panel 1: GCK, HNF1A, HNF1B, HNF4A, PDX1 -lists sensitivity Panel 2: 13 gene panel that includes non-coding variants -ABCC8, BLK, GCK, HNF1A, HNF1B, HNF4A, INS, KCNJ11, KLF11, NEUROD1, PAX4, PDX1, RFX6 -lists non-coding variants Limitations: -complex inversions/balanced translocations -gene conversions -mitochondrial DNA variants/repeat expansion disorders -single exon deletions/duplications 13
14 Genetics of DM type I Type 1 DM: % due to inherited factors -HLA amongst first loci; >50 loci from GWAS -T1DGC aggregated studies for research -41 loci; some well known (HLA, INS, PTPN22, CTLA4, IL2RA) -27/41 were novel -verified loci have candidate genes; allelic heterogeneity Robertson and Rich, 2018 Genetics of DM type I - research predominantly in Europeans - prevalence increasing for other ethnic groups - genetic risk prediction - may help with treatment - slice/exome? Robertson and Rich,
15 Personalized Medicine Whole Exome Sequencing -testing with whole exome sequencing (WES) is effective -variant return has implications for other family members -variant interpretation is likely to change -secondary findings can be medically actionable -returning results in children for adult onset disorders -how should care be delivered? -genetics versus non-genetic professionals -ad hoc versus a dedicated clinic UCSF Personalized Genomics Clinic - provides an identity for genomic services - not a gateway - interpretive and research function - supportive role for clinical testing - consent process, results provision/interpretation - registry function for annual review - database for re-analysis 15
16 UCSF Personalized Genomics Clinic - started in 2013; was 2x per month with 2 physicians - now weekly with 4 physicians - >250 patients - providers: GeneDx, UCLA, Baylor, Ambry, Personalis, Fulgent - now to UCSF - referrals: numerous testing providers from different specialties Able to: - facilitate re-analysis, longitudinal data collection - aid to clinicians in variant interpretation - dedicated clinic enables consistent provider care - trainee education Trios increase yield: 12/143 (8%) proband only 11/143 (8%) duo 120/143 (84%) trio Lee et al., 2014: trio approach increases diagnostic yield -proband only 74/338 (22%) -trio 127/410 (31%) Age group tested can influence yield: 15/143 (10.5%) 1 yr of age 60/143 (42%) 1-5 y 32/143 (22.5%) 6-10 y 20/143 (14%) y 16/143 (11%) 18+ y Posey et al., 2015: diagnostic rate: 85/ % in adults -lower than for Pediatrics; 7% had blended phenotypes 16
17 Patient examples 1. WES can result in unexpected findings that improve care -11 yo male referred to Genetics -sensorineural hearing loss at 2 yo -loss is severe to profound -diagnosed with type I diabetes after presenting with several days of emesis and abdominal pain -cytopenias, including anemia, also noted at presentation -negative Otoscope gene panel (108 gene panel) -chromosomal microarray arr(1-22)x2, (X,Y)x1 -MRI of inner ear normal Patient examples -two pathogenic variants in SLC19A2 -maternally inherited variant: c.484c>t, p.arg162ter -classified as pathogenic -paternally inherited variant: c.515g>a, p.gly172asp -previously reported variant, classified as pathogenic -biallelic pathogenic variants in SLC19A2 are associated with Thiamine-responsive megaloblastic anemia syndrome 17
18 Patient examples 2. Results have implications for other family members: -9 yo male with autism -frameshift variant in TREX1; heterozygous; paternally inherited -father had h/o iritis and fevers -AR TREX1: Aicardi-Goutieres disease -AD TREX1: chillblains; SLE -51 yo male with retinal dystrophy -deleterious variant in PRRT2; heterozygous; unknown inheritance -paroxysmal kinesogenic dyskinesia -benign seizures in grandchild -importance of experienced counselors/genetic interpretation Summary -next-generation technologies are in common use -panel and exome are most frequent tests -differ in consent process, secondary findings -testing has implications for other family members -testing can yield complicated, unanticipated results 18
19 Thank you! UCSF Genomics Medicine Initiative - Pediatrics Co-directors: Neil Risch Pui-yan Kwok Clinicians: Anne Slavotinek Joseph Shieh Marta Sabbadini Wet lab: Jessica van Ziffle Heather Pua Bioinformaticians: Mark Kvale Ugur Hodoglogil Pathology/Fellow: Jude Abadie Ethics: Barbara Koenig Library/Scholarly Communication: Megan Laurance 19
Spectrum of mutations in monogenic diabetes genes identified from high-throughput DNA sequencing of 6888 individuals
Bansal et al. BMC Medicine (2017) 15:213 DOI 10.1186/s12916-017-0977-3 RESEARCH ARTICLE Spectrum of mutations in monogenic diabetes genes identified from high-throughput DNA sequencing of 6888 individuals
More informationBenefits and pitfalls of new genetic tests
Benefits and pitfalls of new genetic tests Amanda Krause Division of Human Genetics, NHLS and University of the Witwatersrand Definition of Genetic Testing the analysis of human DNA, RNA, chromosomes,
More informationCURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi
2 CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE Dr. Bahar Naghavi Assistant professor of Basic Science Department, Shahid Beheshti University of Medical Sciences, Tehran,Iran 3 Introduction Over 4000
More informationUnderstanding The Genetics of Diamond Blackfan Anemia
Understanding The Genetics of Diamond Blackfan Anemia Jason Farrar, MD jefarrar@ About Me Assistant Professor of Pediatrics at University of Arkansas for Medical Sciences & Arkansas Children s Hospital
More informationMaturity-onset diabetes of the young (MODY) is a heterogeneous group
Over the years, different forms of maturity-onset diabetes of the young (MODY) have been identified, with mutations in a number of different genes associated with a MODY-like phenotype. Depending on the
More informationMultiple Copy Number Variations in a Patient with Developmental Delay ASCLS- March 31, 2016
Multiple Copy Number Variations in a Patient with Developmental Delay ASCLS- March 31, 2016 Marwan Tayeh, PhD, FACMG Director, MMGL Molecular Genetics Assistant Professor of Pediatrics Department of Pediatrics
More informationPALB2 c g>c is. VARIANT OF UNCERTAIN SIGNIFICANCE (VUS) CGI s summary of the available evidence is in Appendices A-C.
Consultation sponsor (may not be the patient): First LastName [Patient identity withheld] Date received by CGI: 2 Sept 2017 Variant Fact Checker Report ID: 0000001.5 Date Variant Fact Checker issued: 12
More informationSALSA MLPA probemix P241-D2 MODY mix 1 Lot D2-0716, D As compared to version D1 (lot D1-0911), one reference probe has been replaced.
mix P241-D2 MODY mix 1 Lot D2-0716, D2-0413. As compared to version D1 (lot D1-0911), one reference has been replaced. Maturity-Onset Diabetes of the Young (MODY) is a distinct form of non insulin-dependent
More informationA guide to understanding variant classification
White paper A guide to understanding variant classification In a diagnostic setting, variant classification forms the basis for clinical judgment, making proper classification of variants critical to your
More informationCentoXome FUTURE'S KNOWLEDGE APPLIED TODAY
CentoXome FUTURE'S KNOWLEDGE APPLIED TODAY More genetic information requires cutting-edge interpretation techniques Whole Exome Sequencing For certain patients the combination of symptoms does not allow
More informationHeartland Genetics and Newborn Screening Collaborative Conference
Heartland Genetics and Newborn Screening Collaborative Conference Laurel K. Willig, MD Assistant Medical Director for the Center for Pediatric Genomic Medicine and Joshua E. Petrikin, MD Director of Neonatal
More informationCentoXome FUTURE'S KNOWLEDGE APPLIED TODAY
CentoXome FUTURE'S KNOWLEDGE APPLIED TODAY More genetic information requires cutting-edge interpretation techniques Whole Exome Sequencing For some patients, the combination of symptoms does not allow
More informationPersonalis ACE Clinical Exome The First Test to Combine an Enhanced Clinical Exome with Genome- Scale Structural Variant Detection
Personalis ACE Clinical Exome The First Test to Combine an Enhanced Clinical Exome with Genome- Scale Structural Variant Detection Personalis, Inc. 1350 Willow Road, Suite 202, Menlo Park, California 94025
More informationGenetic Testing and Analysis. (858) MRN: Specimen: Saliva Received: 07/26/2016 GENETIC ANALYSIS REPORT
GBinsight Sample Name: GB4411 Race: Gender: Female Reason for Testing: Type 2 diabetes, early onset MRN: 0123456789 Specimen: Saliva Received: 07/26/2016 Test ID: 113-1487118782-4 Test: Type 2 Diabetes
More informationHow many disease-causing variants in a normal person? Matthew Hurles
How many disease-causing variants in a normal person? Matthew Hurles Summary What is in a genome? What is normal? Depends on age What is a disease-causing variant? Different classes of variation Final
More informationMP Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders
Medical Policy BCBSA Ref. Policy: 2.04.102 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Medicine Related Policies 2.04.59 Genetic Testing for Developmental Delay/Intellectual Disability,
More informationMEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG)
Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Ordering Information Acceptable specimen types: Fresh blood sample (3-6 ml EDTA; no time limitations associated with receipt)
More informationSALSA MLPA probemix P241-D2 MODY mix 1 Lot D As compared to version D1 (lot D1-0911), one reference probe has been replaced.
mix P241-D2 MODY mix 1 Lot D2-0413. As compared to version D1 (lot D1-0911), one reference has been replaced. Maturity-Onset Diabetes of the Young (MODY) is a distinct form of non insulin-dependent diabetes
More informationProtocol. Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders
Whole Exome and Whole Genome Sequencing for Diagnosis of (204102) Medical Benefit Effective Date: 07/01/17 Next Review Date: 03/18 Preauthorization No Review Dates: 03/17 This protocol considers this test
More informationWelcome to the Genetic Code: An Overview of Basic Genetics. October 24, :00pm 3:00pm
Welcome to the Genetic Code: An Overview of Basic Genetics October 24, 2016 12:00pm 3:00pm Course Schedule 12:00 pm 2:00 pm Principles of Mendelian Genetics Introduction to Genetics of Complex Disease
More informationMOLECULAR DIAGNOSIS for X-LINKED INTELLECTUAL DISABILITY
MOLECULAR DIAGNOSIS for X-LINKED INTELLECTUAL DISABILITY Intellectual disability (ID) or mental retardation is characterized by significant limitations in cognitive abilities and social/behavioral adaptive
More informationSETPEG GENETIC TESTING GUIDELINES Version 1.0, 5 th October 2017
SETPEG GENETIC TESTING GUIDELINES Version 1.0, 5 th October 2017 1. The Epilepsy Genetic Diagnostic & Counselling Service at King s Health Partners Professor Deb Pal PhD MRCP (Consultant) deb.pal@nhs.net
More informationWhole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders
Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders Policy Number: 2.04.102 Last Review: 12/2017 Origination: 12/2015 Next Review: 12/2018 Policy Blue Cross and Blue Shield of Kansas
More informationConcurrent Practical Session ACMG Classification
Variant Effect Prediction Training Course 6-8 November 2017 Prague, Czech Republic Concurrent Practical Session ACMG Classification Andreas Laner / Anna Benet-Pagès 1 Content 1. Background... 3 2. Aim
More informationReporting TP53 gene analysis results in CLL
Reporting TP53 gene analysis results in CLL Mutations in TP53 - From discovery to clinical practice in CLL Discovery Validation Clinical practice Variant diversity *Leroy at al, Cancer Research Review
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Leber congenital amaurosis OMIM number for disease 204000 Disease alternative
More informationWhole Exome Sequencing (WES) Whole Exome Sequencing. What Is Whole Exome Sequencing?
Whole Exome Sequencing (WES) Procedure(s) addressed by this policy: Exome (e.g., unexplained constitutional or heritable disorder or syndrome); sequence analysis Sequence analysis, each comparator exome
More informationNature Genetics: doi: /ng Supplementary Figure 1
Supplementary Figure 1 Illustrative example of ptdt using height The expected value of a child s polygenic risk score (PRS) for a trait is the average of maternal and paternal PRS values. For example,
More informationIdentifying Mutations Responsible for Rare Disorders Using New Technologies
Identifying Mutations Responsible for Rare Disorders Using New Technologies Jacek Majewski, Department of Human Genetics, McGill University, Montreal, QC Canada Mendelian Diseases Clear mode of inheritance
More information6/12/2018. Disclosures. Clinical Genomics The CLIA Lab Perspective. Outline. COH HopeSeq Heme Panels
Clinical Genomics The CLIA Lab Perspective Disclosures Raju K. Pillai, M.D. Hematopathologist / Molecular Pathologist Director, Pathology Bioinformatics City of Hope National Medical Center, Duarte, CA
More informationClinical evaluation of microarray data
Clinical evaluation of microarray data David Amor 19 th June 2011 Single base change Microarrays 3-4Mb What is a microarray? Up to 10 6 bits of Information!! Highly multiplexed FISH hybridisations. Microarray
More informationMerging single gene-level CNV with sequence variant interpretation following the ACMGG/AMP sequence variant guidelines
Merging single gene-level CNV with sequence variant interpretation following the ACMGG/AMP sequence variant guidelines Tracy Brandt, Ph.D., FACMG Disclosure I am an employee of GeneDx, Inc., a wholly-owned
More informationFEP Medical Policy Manual
FEP Medical Policy Manual FEP 2.04.102 Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders Effective Date: April 15, 2017 Related Policies: 2.04.59 Genetic Testing for Developmental
More informationLearning Objectives. Genomic Medicine and Primary Care. Clinical Applications of Genome-Level DNA Sequencing. Molecular Medicine.
Presenter Disclosure Information 9:45 10:25am Genomic Medicine and Primary Care SPEAKER Wayne W. Grody, MD, PhD, FACMG, FCAP The following relationships exist related to this presentation: Wayne W. Grody,
More informationDeciphering Developmental Disorders (DDD) DDG2P
Deciphering Developmental Disorders (DDD) DDG2P David FitzPatrick MRC Human Genetics Unit, University of Edinburgh Deciphering Developmental Disorders objectives research understand genetics of DD translation
More informationClinical Spectrum and Genetic Mechanism of GLUT1-DS. Yasushi ITO (Tokyo Women s Medical University, Japan)
Clinical Spectrum and Genetic Mechanism of GLUT1-DS Yasushi ITO (Tokyo Women s Medical University, Japan) Glucose transporter type 1 (GLUT1) deficiency syndrome Mutation in the SLC2A1 / GLUT1 gene Deficiency
More informationGermline Testing for Hereditary Cancer with Multigene Panel
Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with
More informationNature Genetics: doi: /ng Supplementary Figure 1. PCA for ancestry in SNV data.
Supplementary Figure 1 PCA for ancestry in SNV data. (a) EIGENSTRAT principal-component analysis (PCA) of SNV genotype data on all samples. (b) PCA of only proband SNV genotype data. (c) PCA of SNV genotype
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Epileptic encephalopathy, early infantile 4. OMIM number for disease 612164 Disease
More informationNGS in neurodegenerative disorders - our experience
Neurology Clinic, Clinical Center of Serbia Faculty of Medicine, University of Belgrade Belgrade, Serbia NGS in neurodegenerative disorders - our experience Marija Branković, MSc Belgrade, 2018 Next Generation
More informationNGS panels in clinical diagnostics: Utrecht experience. Van Gijn ME PhD Genome Diagnostics UMCUtrecht
NGS panels in clinical diagnostics: Utrecht experience Van Gijn ME PhD Genome Diagnostics UMCUtrecht 93 Gene panels UMC Utrecht Cardiovascular disease (CAR) (5 panels) Epilepsy (EPI) (11 panels) Hereditary
More informationUKGTN Testing Criteria
Test name: Neonatal Diabetes 22 Gene Panel UKGTN Testing Criteria Approved name and symbol of disorder/condition(s): See Appendix 1 Approved name and symbol of gene(s): See Appendix 1 number(s): number(s):
More informationUsing large-scale human genetic variation to inform variant prioritization in neuropsychiatric disorders
Using large-scale human genetic variation to inform variant prioritization in neuropsychiatric disorders Kaitlin E. Samocha Hurles lab, Wellcome Trust Sanger Institute ACGS Summer Scientific Meeting 27
More informationAmerican Psychiatric Nurses Association
Francis J. McMahon International Society of Psychiatric Genetics Johns Hopkins University School of Medicine Dept. of Psychiatry Human Genetics Branch, National Institute of Mental Health* * views expressed
More informationMNGenome Sequencing Test Request Form
MNGenome Sequencing Test Request Form Whole Whole Genome Exome Sequencing Note: Clinical Information and Consent Form are required for MNGenome Orders. *Please note if samples are shipping separately as
More informationVariant Detection & Interpretation in a diagnostic context. Christian Gilissen
Variant Detection & Interpretation in a diagnostic context Christian Gilissen c.gilissen@gen.umcn.nl 28-05-2013 So far Sequencing Johan den Dunnen Marja Jakobs Ewart de Bruijn Mapping Victor Guryev Variant
More informationKey determinants of pathogenicity
Key determinants of pathogenicity Session 6: Determining pathogenicity and genotype-phenotype correlation J. Peter van Tintelen MD PhD Clinical geneticist Academic Medical Center Amsterdam, the Netherlands
More informationAdvances in genetic diagnosis of neurological disorders
Acta Neurol Scand 2014: 129 (Suppl. 198): 20 25 DOI: 10.1111/ane.12232 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd ACTA NEUROLOGICA SCANDINAVICA Review Article Advances in genetic diagnosis
More informationTalking Genomes with Your Patients. Meagan Cochran, MS, CGC Certified Genetic Counselor HudsonAlpha Institute for Biotechnology
Talking Genomes with Your Patients Meagan Cochran, MS, CGC Certified Genetic Counselor HudsonAlpha Institute for Biotechnology Objectives Review the importance of physician familiarity with genomic testing
More informationJULY 21, Genetics 101: SCN1A. Katie Angione, MS CGC Certified Genetic Counselor CHCO Neurology
JULY 21, 2018 Genetics 101: SCN1A Katie Angione, MS CGC Certified Genetic Counselor CHCO Neurology Disclosures: I have no financial interests or relationships to disclose. Objectives 1. Review genetic
More informationVan test naar diagnose naar
Van test naar diagnose naar V therapie op maat Marjolein Kriek, LUMC Joris Veltman, RUNMC Exome diagnostics in genetically heterogeneous disease Joris Veltman, PhD Department of Human Genetics Radboud
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Testing for Hereditary Hearing Loss File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_hereditary_hearing_loss 10/2013 7/2018 7/2019
More informationThe Deciphering Development Disorders (DDD) project: What a genomic approach can achieve
The Deciphering Development Disorders (DDD) project: What a genomic approach can achieve RCP ADVANCED MEDICINE, LONDON FEB 5 TH 2018 HELEN FIRTH DM FRCP DCH, SANGER INSTITUTE 3,000,000,000 bases in each
More informationvariant led to a premature stop codon p.k316* which resulted in nonsense-mediated mrna decay. Although the exact function of the C19L1 is still
157 Neurological disorders primarily affect and impair the functioning of the brain and/or neurological system. Structural, electrical or metabolic abnormalities in the brain or neurological system can
More informationInvestigating rare diseases with Agilent NGS solutions
Investigating rare diseases with Agilent NGS solutions Chitra Kotwaliwale, Ph.D. 1 Rare diseases affect 350 million people worldwide 7,000 rare diseases 80% are genetic 60 million affected in the US, Europe
More informationIntroduction to genetic variation. He Zhang Bioinformatics Core Facility 6/22/2016
Introduction to genetic variation He Zhang Bioinformatics Core Facility 6/22/2016 Outline Basic concepts of genetic variation Genetic variation in human populations Variation and genetic disorders Databases
More informationPERSONALIZED GENETIC REPORT CLIENT-REPORTED DATA PURPOSE OF THE X-SCREEN TEST
INCLUDED IN THIS REPORT: REVIEW OF YOUR GENETIC INFORMATION RELEVANT TO ENDOMETRIOSIS PERSONAL EDUCATIONAL INFORMATION RELEVANT TO YOUR GENES INFORMATION FOR OBTAINING YOUR ENTIRE X-SCREEN DATA FILE PERSONALIZED
More informationGeneticsNow TM. A Guide to Testing Hereditary Conditions in Women & Men. Patient & Physician Information
GeneticsNow TM A Guide to Testing Hereditary Conditions in Women & Men Patient & Physician Information How can BRCA status affect your health? Everyone has BRCA1 and BRCA2 genes. However, sometimes the
More informationWhat s the Human Genome Project Got to Do with Developmental Disabilities?
What s the Human Genome Project Got to Do with Developmental Disabilities? Disclosures Neither speaker has anything to disclose. Phase Two: Interpretation Officially started in October 1990 Goals of the
More informationIntroduction to the Genetics of Complex Disease
Introduction to the Genetics of Complex Disease Jeremiah M. Scharf, MD, PhD Departments of Neurology, Psychiatry and Center for Human Genetic Research Massachusetts General Hospital Breakthroughs in Genome
More informationMEDICAL GENOMICS LABORATORY. Non-NF1 RASopathy panel by Next-Gen Sequencing and Deletion/Duplication Analysis of SPRED1 (NNP-NG)
Non-NF1 RASopathy panel by Next-Gen Sequencing and Deletion/Duplication Analysis of SPRED1 (NNP-NG) Ordering Information Acceptable specimen types: Blood (3-6ml EDTA; no time limitations associated with
More informationAssessing Laboratory Performance for Next Generation Sequencing Based Detection of Germline Variants through Proficiency Testing
Assessing Laboratory Performance for Next Generation Sequencing Based Detection of Germline Variants through Proficiency Testing Karl V. Voelkerding, MD Professor of Pathology University of Utah Medical
More informationSurgery in Congenital Hyperinsulinismless. Winfried Barthlen
Surgery in Congenital Hyperinsulinismless may be more Winfried Barthlen congenital hyperinsulinism - very rare (1:40.000) - uncontrolled insulin secretion - life threatening hypoglycemia symptoms - unconsciousness,
More informationGenetic Counselling in relation to genetic testing
Genetic Counselling in relation to genetic testing Dr Julie Vogt Consultant Geneticist West Midlands Regional Genetics Service September 2016 Disclosures for Research Support/P.I. Employee Consultant Major
More informationGenetics and Genetic Testing for Autism:
STAR Training 2/22/2018 Genetics and Genetic Testing for Autism: Demystifying the Journey to Find a Cause Alyssa (Ah leesa) Blesson, MGC, CGC Certified Genetic Counselor Center for Autism and Related Disorders
More informationSingle Gene (Monogenic) Disorders. Mendelian Inheritance: Definitions. Mendelian Inheritance: Definitions
Single Gene (Monogenic) Disorders Mendelian Inheritance: Definitions A genetic locus is a specific position or location on a chromosome. Frequently, locus is used to refer to a specific gene. Alleles are
More informationIllinois AACE Annual Meeting October 13, 2018
Illinois AACE Annual Meeting October 13, 2018 The Importance of Making a Diagnosis: The case for Monogenic Diabetes Louis H. Philipson MD, PhD Director, Kovler Diabetes Center Professor of Medicine and
More informationChapter 4 PEDIGREE ANALYSIS IN HUMAN GENETICS
Chapter 4 PEDIGREE ANALYSIS IN HUMAN GENETICS Chapter Summary In order to study the transmission of human genetic traits to the next generation, a different method of operation had to be adopted. Instead
More informationMNG Exome Sequencing Test Request Form
Whole Exome Sequencing MNG Exome Sequencing Test Request Form Note: Clinical Information and Consent Form are required for MNG Exome Orders. IMPORTANT: Please note if any additional samples will be shipped
More informationUNIVERSITY OF PENNSYLVANIA GENETIC DIAGNOSTIC LABORATORY
GNA FOP Familial Adenomatous Polyposis Beckwith-Wiedemann Syndrome Methylation and high resolution copy number analysis of 11p15.5 with automatic reflex to CDKN1C if negative Methylation analysis of 11p15.5
More informationNeurogenetics Genetic Testing and Ethical Issues
Neurogenetics Genetic Testing and Ethical Issues Grace Yoon, MD, FRCP(C) Divisions of Neurology and Clinical and Metabolic Genetics The Hospital for Sick Children Objectives 1) To recognize the ethical
More informationIntroduction to Evaluating Hereditary Risk. Mollie Hutton, MS, CGC Certified Genetic Counselor Roswell Park Comprehensive Cancer Center
Introduction to Evaluating Hereditary Risk Mollie Hutton, MS, CGC Certified Genetic Counselor Roswell Park Comprehensive Cancer Center Objectives Describe genetic counseling and risk assessment Understand
More informationCorporate Medical Policy
Corporate Medical Policy Invasive Prenatal (Fetal) Diagnostic Testing File Name: Origination: Last CAP Review: Next CAP Review: Last Review: invasive_prenatal_(fetal)_diagnostic_testing 12/2014 3/2018
More informationCNNH NeuroGenomics Program Peer-to-Peer Service Consent/Information Form
CNNH NeuroGenomics Program Peer-to-Peer Service Consent/Information Form WHO WEARE The Center for Neurological and Neurodevelopmental Health (CNNH) is an innovative patient- and family-centered "Specialty
More informationComputational Systems Biology: Biology X
Bud Mishra Room 1002, 715 Broadway, Courant Institute, NYU, New York, USA L#4:(October-0-4-2010) Cancer and Signals 1 2 1 2 Evidence in Favor Somatic mutations, Aneuploidy, Copy-number changes and LOH
More informationPage: 1 of 15. Whole Exome and Whole Genome Sequencing for Diagnosis of Patients With Suspected Genetic Disorders
Last Review Status/Date: December 2015 Page: 1 of 15 Sequencing for Diagnosis of Patients Description Whole exome sequencing (WES) is targeted sequencing of the subset of the human genome that contains
More informationImplementation of the DDD/ClinGen OGT (CytoSure v3) Microarray
Implementation of the DDD/ClinGen OGT (CytoSure v3) Microarray OGT UGM Birmingham 08/09/2016 Dom McMullan Birmingham Women's NHS Trust WM chromosomal microarray (CMA) testing Population of ~6 million (10%)
More informationTHE IMPORTANCE OF GENETICS WHEN TREATING HYPERINSULINISM
THE IMPORTANCE OF GENETICS WHEN TREATING HYPERINSULINISM HEATHER MCKNIGHT-MENCI, MSN, CRNP CHILDREN S HOSPITAL OF PHILADELPHIA WHAT IS HYPERINSULINISM? The leading cause of hypoglycemia in infants and
More informationInterpretation can t happen in isolation. Jonathan S. Berg, MD/PhD Assistant Professor Department of Genetics UNC Chapel Hill
Interpretation can t happen in isolation Jonathan S. Berg, MD/PhD Assistant Professor Department of Genetics UNC Chapel Hill With the advent of genome-scale sequencing, variant interpretation is increasingly
More informationNGS for Cancer Predisposition
NGS for Cancer Predisposition Colin Pritchard MD, PhD University of Washington Dept. of Lab Medicine AMP Companion Society Meeting USCAP Boston March 22, 2015 Disclosures I am an employee of the University
More informationMolecular Diagnostic Laboratory 18 Sequencing St, Gene Town, ZY Tel: Fax:
Molecular Diagnostic Laboratory 18 Sequencing St, Gene Town, ZY 01234 Tel: 555-920-3333 Fax: 555-920-3334 www.moldxlaboratory.com Patient Name: Jane Doe Specimen type: Blood, peripheral DOB: 04/05/1990
More informationExploding Genetic Knowledge in Developmental Disabilities. Disclosures. The Genetic Principle
Exploding Genetic Knowledge in Developmental Disabilities How to acquire the data and how to make use of it Elliott H. Sherr MD PhD Professor of Neurology & Pediatrics UCSF Disclosures InVitae: clinical
More informationOutline. Next-Generation Sequencing. The Application of Genomic Medicine in Clinical and Laboratory Practice
Outline The Application of Genomic Medicine in Clinical and Laboratory Practice Jerry Feldman, MD, PhD, FACMG Medical Director, Division of Laboratory Genetics and Molecular Pathology, Detroit Medical
More informationLecture 20. Disease Genetics
Lecture 20. Disease Genetics Michael Schatz April 12 2018 JHU 600.749: Applied Comparative Genomics Part 1: Pre-genome Era Sickle Cell Anaemia Sickle-cell anaemia (SCA) is an abnormality in the oxygen-carrying
More informationPrecision Medicine and Genetic Counseling : Is Yes always the correct answer?
Precision Medicine and Genetic Counseling : Is Yes always the correct answer? Beverly M. Yashar, MS, PhD, CGC Director, Graduate Program in Genetic Counseling Professor, Department of Human Genetics. (yashar@umich.edu)
More informationGenetics and Genomics: Applications to Developmental Disability
Tuesday, 12:30 2:00, B1 Objective: Genetics and Genomics: Applications to Developmental Disability Helga Toriello 616-234-2712 toriello@msu.edu Identify advances in clinical assessment and management of
More informationGenetic Considerations in Young Children with Developmental Delays
Early Intervention Training Program at the University of Illinois at Urbana-Champaign presents Genetic Considerations in Young Children with Developmental Delays The webinar will begin at (1:30 PM CST).
More informationEgypt 90 Million People Power Seven Thousands Year Culture 29 Governorates
Egypt 90 Million People Power Seven Thousands Year Culture 29 Governorates Recent advances in Molecular Medicine: Changing the practice of neurology Presentation by Nagwa Meguid, Prof. of Human Genetics
More informationHome Brewed Personalized Genomics
Home Brewed Personalized Genomics The Quest for Meaningful Analysis Results of a 23andMe Exome Pilot Trio of Myself, Wife, and Son February 22, 2013 Gabe Rudy, Vice President of Product Development Exome
More informationGenetic causes 90% Other causes 10% No variants are found in known genes associated with ADPKD
CLINICIAN PRODUCT SHEET Genome.One Polycystic Kidney Disease Test Genome.One offers a diagnostic genetic test for patients with polycystic kidney disease (PKD), with a focus on the most common form, autosomal
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing
More informationMEDICAL GENOMICS LABORATORY. Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG)
Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG) Ordering Information Acceptable specimen types: Blood (3-6ml EDTA; no time limitations associated with receipt) Saliva (OGR-575 DNA Genotek;
More informationBasic Definitions. Dr. Mohammed Hussein Assi MBChB MSc DCH (UK) MRCPCH
Basic Definitions Chromosomes There are two types of chromosomes: autosomes (1-22) and sex chromosomes (X & Y). Humans are composed of two groups of cells: Gametes. Ova and sperm cells, which are haploid,
More informationSo, now, that we have reviewed some basics of cancer genetics I will provide an overview of some common syndromes.
Hello. My name is Maureen Mork and I m a Certified Genetic Counselor in the Clinical Cancer Genetics Program at The University of Texas MD Anderson Cancer Center. I ll be lecturing today on the Cancer
More informationBIOCHEMICAL AND MOLECULAR HETEROGENEITY IN CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY
BIOCHEMICAL AND MOLECULAR HETEROGENEITY IN CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY Carmen Sousa, Helena Fonseca, Hugo Rocha, Ana Marcão, Laura Vilarinho, Luísa Diogo, Sílvia Sequeira, Cristina Costa,
More informationThe Genetics of VHL. Proper tissue growth - controlled traffic. How human cells and tissue grow and die?
How human cells and tissue grow and die? The Genetics of VHL Xia Wang MD PhD Oct, 2017 Proper tissue growth - controlled traffic Normal tissue growth is regulated by many genetic factors Safe traffic is
More informationUAB P30 CORE A: The Hepato-Renal Fibrocystic Diseases Translational Resource
PKD Foundation UAB P30 CORE A: The Hepato-Renal Fibrocystic Diseases Translational Resource http://www.arpkdstudies.uab.edu/ Director: Co-Director: Lisa M. Guay-Woodford, MD William E. Grizzle, MD, PhD
More informationRiunione Regionale SIN Campania
Riunione Regionale SIN Campania Dott.ssa Maria Lieto Dipartimento di Neuroscienze, Università Federico II Napoli Salerno, 14 dicembre 2018 HEREDITARY ATAXIAS SCAs (35 genes) ARCAs (94 genes) Diagnosis?
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISORDER/CONDITION POPULATION TRIAD Submitting laboratory: Exeter RGC Approved: Sept 2013 1. Disorder/condition
More informationCS2220 Introduction to Computational Biology
CS2220 Introduction to Computational Biology WEEK 8: GENOME-WIDE ASSOCIATION STUDIES (GWAS) 1 Dr. Mengling FENG Institute for Infocomm Research Massachusetts Institute of Technology mfeng@mit.edu PLANS
More information